

1 Arbovirus surveillance in pregnant women in north-central Nigeria, 2019-2022

2 Jerry Ogwuche^{1,a}, Charlotte Ajeong Chang^{2,a}, Olukemi Ige³, Atiene S. Sagay³, Beth Chaplin²
3 Makshwar L. Kahansim³, Michael Paul³, Michael Elujoba¹, Godwin Imade³, Georgenia
4 Kweashi¹, Yu-Ching Dai⁴, Szu-Chia Hsieh⁴, Wei-Kung Wang⁴, Donald J. Hamel², Phyllis J.
5 Kanki²

6 ¹ Our Lady of Apostles Hospital, Jos, Nigeria;

7 ² Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public
8 Health, Boston, Massachusetts, USA;

9 ³ Jos University Teaching Hospital, University of Jos, Jos, Nigeria;

10 ⁴ Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns
11 School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA

12 **Correspondence:** Phyllis J. Kanki (pkanki@hsph.harvard.edu)

13 ^a These authors contributed equally.

14 Abstract

15 The adverse impact of Zika (ZIKV), dengue (DENV), and chikungunya (CHIKV) virus infection
16 in pregnancy has been recognized in Latin America and Asia but is not well studied in Africa.

17 In Nigeria, we screened 1006 pregnant women for ZIKV, DENV and CHIKV IgM/IgG by rapid
18 test (2019-2022). Women with acute infection were recruited for prospective study and infants
19 were examined for any abnormalities from delivery through six months. A subset of rapid test-
20 reactive samples were confirmed using virus-specific ELISAs and neutralization assays.

21 Prevalence of acute infection (IgM+) was 3.8%, 9.9% and 11.8% for ZIKV, DENV and CHIKV,
22 respectively; co-infections represented 24.5% of all infections. Prevalence in asymptomatic
23 women was twice the level of symptomatic infection. We found a significant association
24 between acute maternal ZIKV/DENV/CHIKV infection and any gross abnormal birth outcome
25 ($p=0.014$).

26 Further prospective studies will contribute to our understanding of the clinical significance of
27 these endemic arboviruses in Africa.

28 Running Title

29 ZIKV, DENV and CHIKV in pregnancy in Nigeria

30

31 **Keywords:** Zika, dengue, chikungunya virus, arbovirus, pregnancy, microcephaly, West Africa,
32 Nigeria

33

34 **Introduction**

35 In recent times, the emergence and re-emergence of Zika (ZIKV), dengue (DENV), and
36 chikungunya (CHIKV) viruses have caused significant outbreaks of human disease globally (1,
37 2). Genomic and phylogenetic studies have delineated the origins and evolution of these
38 arboviruses, which each have multiple Asian or American strains and lineages that expanded
39 from ancestral African strains (3, 4). Although originally discovered in sub-Saharan Africa,
40 research on these viruses and their biology in people on the continent has been limited.
41 Arbovirus outbreaks in Africa likely go unrecognized due to their non-specific clinical
42 presentations shared with malaria and typhoid and the lack of diagnostic capabilities for
43 surveillance.

44 Across the globe, 90% of the estimated 200 million annual pregnancies occur in
45 geographic regions with endemic or epidemic arboviruses (5). The 2015-2016 ZIKV outbreak in
46 the Americas identified the teratogenic threat of ZIKV and renewed interest in the impact of
47 other arboviruses on pregnancy and infant outcomes. Studies from outbreaks of ZIKV, DENV,
48 and CHIKV have shown an increased risk of severe disease in pregnant women as well as fetal
49 loss, prematurity, microcephaly and other birth defects or severe neonatal infection (5). While
50 ZIKV, DENV and CHIKV infections may have similar clinical presentations, they exert
51 temporally distinct impacts over the course of pregnancy. While antenatal ZIKV may result in
52 microcephaly and congenital Zika syndrome (CZS), antenatal DENV is associated with preterm
53 delivery and stillbirth, and CHIKV primarily impacts intra-partum outcomes resulting in
54 neonatal disease and neurodevelopmental delays.

55 Nigeria is the most populous country in Africa, with over 200 million inhabitants (6), it is
56 large (357,000 square miles) with diverse terrains and climatic regions, and over 70% of the

57 population lives in rural areas. Global environmental mapping studies suggest that in Africa,
58 roughly 453 million people live in areas suitable for ZIKV transmission, of which 111 million
59 live in Nigeria, the nation at highest risk on the continent (7). Previously, we reported that ZIKV
60 has been circulating in West Africa for at least two decades (8). The seroprevalence of ZIKV
61 IgM was 6.4% in Nigerian patients and phylogenetic analysis showed that the ZIKVs belonged
62 to the African lineage. As noted by the WHO, a linkage between a ZIKV strain circulating in
63 Africa and microcephaly or other complications would have a significant impact on global risk
64 assessments (9). The ZIKV outbreak in the Americas raised the question of whether pre-existing
65 cross-reactive immunity or herd immunity may have resulted in the lack of detection of ZIKV-
66 induced microcephaly in Africa (10).

67 In recent decades, DENV has emerged as a public health threat in Asia and Latin
68 America. Although this arbovirus has been described in Africa since the late 19th century and the
69 *Aedes spp.* mosquito vector is ubiquitous, the epidemiology and public health importance in
70 Africa is largely unknown (11). Although DENV outbreaks have been reported on the continent,
71 diagnostics are lacking and febrile illnesses are frequently attributed to malaria. Halstead and
72 others have considered genetic factors may be protective from disease based on the differential
73 disease manifestations by race, as seen in outbreaks in Cuba (12, 13). Others have suggested that
74 circulating endemic flaviviruses in Africa may provide cross-protection from severe dengue
75 disease (14).

76 The impact of DENV infection during pregnancy on birth outcomes has been reported
77 largely in case reports and case series from Asia and the Americas (5). In a meta-analysis,
78 symptomatic dengue disease in pregnant women was associated with an increased risk of

79 miscarriage (OR=3.51, 95% CI 1.15-10.77), stillbirth (RR=6.7, 95% CI 2.1-21.3), preterm birth
80 (OR=1.71, 95% CI 1.06-2.76) and low birthweight for gestational age (1.41, 0.90-2.21) (15).

81 Chikungunya is an alphavirus transmitted, like ZIKV and DENV, by *Aedes aegypti* and
82 *Aedes albopictus*. *Aedes albopictus* have been shown to deliver more than one arbovirus in their
83 saliva (16). *Aedes aegypti* could be infected with and transmit all combinations of CHIKV,
84 DENV-2 and ZIKV (17, 18). The different clinical consequences of single versus multiple co-
85 infections are not clear (19, 20). The 2005-6 CHIKV outbreak on Reunion Island was estimated
86 to have infected one-third of the African island's population (>250,000) (21). The risk of CHIKV
87 vertical transmission was highest in the intrapartum period at ~50% transmission (22). Severe
88 neonatal disease was also noted with sepsis-like illness, encephalitis, convulsions and death;
89 exceptional cases of fetal demise were attributed to in utero CHIKV (23). In subsequent follow-
90 up of the cohort of CHIKV-exposed children, 51% had neurodevelopmental delays compared to
91 15% of uninfected controls (24, 25).

92 Despite significant global risk for disease by ZIKV, DENV and CHIKV, our
93 understanding of the epidemiology and pathogenesis of these arboviruses largely relies on
94 research conducted in Asia and the Americas. The ZIKV epidemic in the Americas and its link to
95 birth defects raised new research questions on the consequences of arbovirus infection in
96 pregnancy. Given the high risk for arbovirus infection in Africa, our prospective study of
97 symptomatic and asymptomatic pregnant women in Nigeria sought to better describe the
98 epidemiology of arbovirus infection in West Africa and its potential impact on pregnancy and
99 infant outcomes.

100 **Methods**

101 **Study design and participants**

102 Pregnant women ≥ 18 years of age attending the antenatal clinics at Jos University Teaching
103 Hospital and Our Lady of Apostles Hospital in Jos, north-central Nigeria were recruited for
104 arbovirus screening from April 1, 2019 to January 31, 2022. Women presenting with any of six
105 common Zika symptoms: fever $\geq 37.5^{\circ}\text{C}$, rash, headache, arthralgia, conjunctivitis, or myalgia
106 were recruited for a screening questionnaire and rapid test for ZIKV, DENV and CHIKV. One
107 asymptomatic woman was recruited for every four symptomatic women. All women provided
108 written informed consent for the screening, and separate informed consent for participation with
109 their infants in the prospective follow-up study. The study was approved by the institutional
110 review boards of the Jos University Teaching Hospital and the Harvard T.H. Chan School of
111 Public Health.

112 Participating women provided a finger prick sample for the DPP[®] ZCD IgM/IgG rapid
113 test (ChemBio, Medford, NY). They were administered a questionnaire that collected
114 information on participant demographics, clinical history, exposure, and symptoms and had a
115 brief clinical examination. The rapid test result was provided to the women within 30 minutes
116 along with appropriate counseling. The DPP[®] ZCD IgM/IgG rapid test is CE-marked with 99-
117 100% sensitivity and specificity for each virus and antibody isotype. All ZIKV, DENV, or
118 CHIKV rapid test IgM and IgM/IgG positive women (symptomatic or asymptomatic) were
119 recruited for the observational prospective study. At all routine antenatal visits and through
120 delivery, women were examined for symptoms and provided blood and urine samples, a subset
121 of which were tested for IgM antibodies by ELISA, neutralization tests and for nucleic acid
122 detection.

123 At delivery, infants were examined for any abnormal clinical outcomes, including
124 microcephaly and signs of congenital Zika syndrome. Any adverse pregnancy outcomes,
125 including miscarriage, stillbirth, and premature delivery were also documented. Infants were
126 followed at their routine follow-up visits: 6 weeks, 10 weeks, 14 weeks, and 6 months. They
127 were observed for any developmental abnormalities, including ocular examinations.
128 Microcephaly was defined as head circumference with Z-score less than or equal to -2 standard
129 deviations (SD), calculated as the difference between the head circumference and the median
130 head circumference of a reference population (same age and sex) divided by the SD for the
131 reference population used by the WHO Multicentre Growth Reference Study (26). An infant was
132 defined as low weight if their birth weight Z-score was less than -2 SD for their age and sex. An
133 infant was defined as preterm if delivered earlier than 37 weeks gestational age, the Fenton
134 growth charts were used to calculate Z-scores for head circumference and weight for preterm
135 infants, as used at the hospitals (27, 28).

136 **Confirmation of arbovirus serology**

137 Anti-ZIKV and anti-DENV IgM and IgG were determined by previously described ELISAs
138 using DENV and ZIKV envelope protein fusion-loop (FL) mutated virus-like particles (VLP) as
139 antigens, which greatly reduced cross-reactivities from other flaviviruses (29). The
140 sensitivity/specificity of DENV FL-VLP-based IgM and IgG ELISAs were 75.0/95.8% and
141 100.0/93.0%, respectively; the sensitivity/specificity of ZIKV FL-VLP-based IgM and IgG
142 ELISAs were 90.0/99.3% and 100.0/83.3%, respectively. Previously described ZIKV and
143 DENV NS1 IgG ELISAs were also used to distinguish previous DENV and ZIKV infections
144 (30).

145 Microneutralization test using Vero cells and DENV (DENV1-Hawaii, DENV2-NGC,
146 DENV3-H87, DENV4-H241), or ZIKV (PRVABC59 strain) was performed in 96-well plates as
147 previously described, and 90% neutralization (NT₉₀) titers to DENV1-4 and ZIKV were
148 determined (31). NT₉₀ titers <10 to all 5 flaviviruses tested were designated as DENV- and
149 ZIKV-naïve, ≥10 to only one virus as primary infection (32), ≥10 to two or more viruses as
150 multiple flavivirus infections. The neutralization test for CHIKV was performed using a CHIKV
151 pseudovirus assay (33). The % neutralization was determined and NT₅₀ titer was the serum
152 dilution that reached 50% neutralization using 4-parameter nonlinear regression analysis
153 (GraphPad 6.0).

154 We analyzed the sensitivity and specificity of the DPP® ZCD IgM/IgG rapid test using
155 146 convalescent-phase samples from RT-PCR-confirmed DENV, ZIKV and CHIKV cases, and
156 naïve samples (33-35). The sensitivity/specificity of CHIKV-, ZIKV- and DENV-IgM was
157 90.9/95.1%, 81.0/94.2% and 80.0/82.0%, respectively (Supplementary Table 1).

158 Viral RNA was subjected to nested or semi-nested PCR targeting a conserved region of
159 the NSP2 gene of CHIKV, 3'-untranslated region of DENV, and NS5 or NS4B gene of ZIKV (36,
160 37). Electrophoresis of RT-PCR products and bands with the predicted size were purified for
161 sequencing; assay details provided upon request.

162 **Statistical analysis**

163 Descriptive statistics of demographic and clinical data described the study population. The X²
164 test was used in bivariate analyses to test for associations between demographic and exposure
165 variables and arbovirus infection. Variables significant at p≤0.20 in bivariate analyses were
166 included in the multivariate logistic regression model, and backwards elimination used to build

167 the final model predicting acute arbovirus infection, which retained variables significant at
168 $p \leq 0.05$.

169 For the prospective follow-up study, we used the two-sided Fisher's exact test to compare
170 outcomes of infants born to arbovirus rapid test IgM-positive mothers to outcomes recorded in
171 the general labor and delivery population registers at JUTH and OLA; we repeated this analysis
172 with just the infants born to ELISA- and NT-confirmed arbovirus-positive mothers. For the
173 overall comparison of any abnormal birth outcome, study infants were not double-counted if they
174 had more than one abnormal category. Stata v.15.1 (StataCorp, College Station, TX, USA)
175 software was used for the statistical analyses.

176 **Results**

177 From April 2019 to January 2022, we recruited 1006 consenting pregnant women at their
178 antenatal care visit, 478 at JUTH and 528 at OLA. One-third of women (312/1006, 31.0%)
179 showed antibody responses to one or more of the arboviruses, with 19.9% IgM or IgM/IgG
180 reactive and 11.1% reactive to IgG only (Figure 1). Acute or recent arbovirus prevalence,
181 defined by IgM or IgM/IgG seropositivity, was ZIKV 1.4% (14/1006), DENV 6.0% (60/1006)
182 and CHIKV 7.7% (77/1006), ZIKV+DENV 0.7% (7/1006), ZIKV+CHIKV 0.9% (9/1006),
183 DENV+CHIKV 2.5% (25/1006) and ZIKV+CHIKV+DENV 0.8% (8/1006) (Table 1).

184 Acute infected women with IgM+ reactivity showed significant variation by arbovirus
185 and time. Higher recruitment of symptomatic women corresponded to the three rainy seasons
186 over the study period (Figure 2). To evaluate temporal trends, the study was divided into three
187 time periods: April 2019-March 2020, April 2020-March 2021, and April 2021-January 2022.
188 The IgM+ prevalence for any arbovirus was 26.7% (88/330) in the first time period and reduced

189 to 16.0% (59/368) in period 2 and 17.2% (53/308) in period 3. Age-specific arbovirus
190 prevalence demonstrated a characteristic pattern of endemic infection (Supplementary Figure
191 S1).

192 We analyzed baseline characteristics of pregnant women to identify risks for acute (IgM)
193 arbovirus infection (Table 2). In bivariate analysis, OLA clinic, study year 2019-2020, age 25-34
194 years, Igbo/other ethnicity, and unemployment status were associated with acute infection.
195 Questionnaire data on mosquito exposure also found that majority of daytime outdoors, travel to
196 locales with mosquitoes, and mosquito bites during pregnancy were associated with acute
197 arbovirus infection. In multiple logistic regression using clinic as a cluster variable, age 25-34
198 years, study year 2019-2020, unemployment status, majority outdoor day environment, travel to
199 locales with mosquitoes, and prior mosquito bites (>2 weeks) remained statistically significant.

200 Unexpectedly, lower rates of acute arbovirus infection were observed in women who
201 reported symptoms at screening 132/787 (16.8%) compared to 68/219 (31.1%) in asymptomatic
202 women (Fishers exact $p < 0.001$), ratio of asymptomatic to symptomatic of 2:1. We failed to
203 observe high levels of IgG seroprevalence or hyper-endemic arbovirus infection in the absence
204 of IgM, with relatively low levels of IgG reactivity to all three arboviruses (1.7-6.9%).

205 We compared birth outcomes for 101 ZIKV/DENV/CHIKV rapid test IgM-positive
206 women to 5930 JUTH and OLA delivery records from May 2019 to May 2021 (Table 3). We
207 found potential associations between maternal ZIKV/DENV/CHIKV infection during pregnancy
208 and macerated stillbirth ($p = 0.017$), asymmetric intrauterine growth retardation ($p = 0.017$),
209 microcephaly ($p < 0.001$), cleft lip/palate ($p = 0.017$), polydactyly ($p = 0.017$), and multiple
210 congenital anomalies ($p < 0.001$) of the infant. We found a significant association between

211 maternal ZIKV/DENV/CHIKV infection during pregnancy and any adverse or abnormal gross
212 birth outcome ($p=0.014$).

213 We conducted additional confirmatory serologic studies on a subset of samples from the
214 arbovirus IgM-positive women. Using FL-mutated VLP ELISAs, NS1-based ELISAs,
215 microneutralization or pseudovirus neutralization tests, we confirmed 37 samples and re-
216 compared the delivery outcomes of these confirmed arbovirus infected women to the overall
217 hospital control deliveries (Table 3). Microcephaly was associated with confirmed maternal IgM-
218 positive status ($p=0.019$), confirmed maternal ZIKV/DENV/CHIKV infection during pregnancy
219 remained significantly associated with any gross abnormal birth outcome ($p=.005$). We also
220 identified and described 33 infants from May 2019-May 2021 with any abnormal observations
221 recorded from birth through six months, including transient weight or head circumference and
222 neonatal jaundice or sepsis, which were not recorded in the birth registers, with the mother's
223 serology results (Supplementary Table S2).

224 **Discussion**

225 Our surveillance study in pregnant women provides new insights into the epidemiology of
226 arbovirus infection in a West African setting. Spanning three rainy seasons, our study detected
227 regular peaks in symptomatic pregnant women enrollment coincident with rainy seasons and
228 heightened risk for mosquito transmission. We described acute infection with ZIKV, DENV and
229 CHIKV continuously throughout the 34-month study, which decreased during the COVID-19
230 pandemic, with an overall IgM prevalence of 3.8% ZIKV, 9.9% DENV, and 11.8% CHIKV.

231 Geographic regions with endemic *Aedes sp.* may be at risk for co-circulation of ZIKV,
232 DENV and CHIKV, as well as other related and serologically cross-reactive viruses such as

233 Yellow Fever virus (YFV), West Nile virus (WNV), Usutu virus and the alphavirus O'nyong-
234 nyong virus. The similar non-distinguishing and transient clinical presentations and diagnostic
235 assays compromised by cross-reactivity hinder disease surveillance efforts. Comprehensive
236 arbovirus surveillance is rarely performed in most African settings where inadequate
237 infrastructure and/or the cost of testing are prohibitive. As a result, most studies are cross-
238 sectional surveys on febrile patients that focus on a single viral pathogen, limiting our
239 understanding of arbovirus co-infection. We found significant ZIKV, DENV, and CHIKV co-
240 infections in pregnant women comprising 24.5% of all IgM-positive infections. Co-infection
241 with CHIKV and DENV (with or without ZIKV) represented 67.3% of the co-infections and
242 18.4% ZIKV-CHIKV. In Brazil and Colombia, pregnant women with multiple arbovirus
243 infections have been described (38, 39). Case reports of congenital co-infection of CHIKV and
244 ZIKV described increased disease manifestations often leading to miscarriage (40). The clinical
245 significance of single versus multiple co-infections remains unclear.

246 Although DENV, ZIKV and CHIKV have historical origins in Africa, severe arbovirus
247 disease outbreaks have been only rarely described. For ZIKV, the rapid geographic dispersal and
248 distinct disease manifestations in the 2015-16 epidemic in the Americas and the re-emergence in
249 the 2015 Cape Verde and 2016 Guinea Bissau outbreaks on the African continent suggest that
250 this may be changing (9). However, it is notable that these two outbreaks were associated with
251 the ZIKV of Asian lineage. We have previously reported a 6% seroprevalence in febrile West
252 Africans (2004-2016) with African lineage ZIKV (8), similar to the reported 6.2% IgM
253 seroprevalence by ZIKV NS1-based ELISA in north-central Nigeria in 2018 (41). This low
254 prevalence profile may be explained by the mosquito vectors; lower ZIKV transmission potential

255 has been described for native *A. aegypti* species compared to sub-species from Asia or the
256 Americas, also seen in YFV and DENV transmission (42).

257 Worldwide, DENV is considered one of the most widely distributed arboviruses with
258 over 100 million annual infections. An analysis of 2020 data from 23 countries in southeast Asia
259 and Latin America described reduced dengue transmission associated with COVID-19
260 restrictions which could not be explained by seasonal dengue cycles or underreporting (43, 44).
261 In our time period analysis, we also saw a reduction in acute IgM-positive arbovirus infections in
262 pregnant women from 26.7% in the first time period to 16.0% and 17.2% from 2020-2022,
263 coinciding with the COVID-19 pandemic. The Nigerian governmental response to the COVID-
264 19 pandemic began in March 2020, which closed national and state borders and instituted weeks
265 of stay-at-home orders, followed by restricted movement and curfews. Antenatal attendance
266 dropped by 50% for several months and COVID-19 surges along with other imposed public
267 health restrictions likely limited population movement and gathering.

268 In the literature, most studies of ZIKV and DENV are based on hospital-based disease
269 surveillance whereby patients presenting with fever or other significant flavivirus symptoms
270 present to healthcare settings for care. By contrast, our study population consisted of healthy and
271 mildly symptomatic pregnant women attending antenatal clinics (Supplementary Table S3). We
272 found that the rate of acute arbovirus infection was two times higher in asymptomatic women
273 (31.1%) compared with mildly symptomatic women (16.8%). Other arbovirus studies have
274 reported that most infections are asymptomatic and symptoms non-specific, with the ratio of
275 symptomatic to inapparent infection ranging from 1:1 to 1:19 with DENV and 1:0.03 to 1:1.2
276 with CHIKV (45-48). In the 2007 ZIKV outbreaks in Yap Island, household surveillance
277 estimated a ratio of 1 symptomatic to every 4.4 asymptomatic infected individuals (49, 50).

278 Endemic exposure in Africa and Asia may limit recognized outbreaks via herd immunity, which
279 could be imparted by multiple cross-reacting flaviviruses.

280 High arbovirus seroprevalence rates have been reported in serosurveys among febrile
281 hospital outpatients in Nigeria. In a meta-analysis of CHIKV in Nigeria, 7 cross-sectional studies
282 contributed to the pooled anti-CHIKV IgM prevalence of 26.7% and 29.3%; these studies were
283 conducted in the North-east and South-west of the country, where geographic region was a
284 predictor for high seroprevalence (51). In contrast, our study demonstrated lower rates of both
285 acute IgM and convalescent/remote IgG seroreactivity throughout the study period, consistent
286 with our previous studies (8). Differences in geographic region, health status of study
287 participants and serologic assays employed may provide some explanation for the apparent
288 differences in results from our study and previous studies in the country.

289 Microcephaly in ZIKV infected infants in the 2015-16 outbreak of the Americas
290 increased interest in the pathologic effects of these previously poorly studied flaviviruses.
291 ZIKV, DENV and CHIKV have been associated with adverse pregnancy outcomes including
292 miscarriage, stillbirths and perinatal death (22, 52, 53). In our study, microcephaly was found in
293 6/101 (5.9%) acute arbovirus-infected women compared to 32/5930 (0.5%) in the control
294 hospital deliveries, ($p < 0.001$). We were not able to confirm arbovirus transmission in all infants
295 born to IgM+ mothers, so we are cautious in interpreting these results. Nonetheless, the
296 significant differences in infants born to arbovirus-infected women compared to the community
297 control population warrant future study. Acute arbovirus infection was significantly associated
298 with adverse and gross abnormal birth outcomes in both rapid test and confirmed subset analysis
299 ($p = 0.014$ and 0.005 , respectively). We also report significant associations with multiple
300 congenital anomalies ($p < 0.001$), which should be studied further.

301 Our study has several limitations. The low-level prevalence rates of individual arbovirus
302 infections and high rates of co-infections made direct associations with maternal and infant
303 outcomes difficult. We were not able to confirm all rapid test IgM/IgG samples with other
304 confirmatory assays. As our study population was pregnant women, some arbovirus symptoms
305 are conflated with common pregnancy symptoms. The prospective study design and evaluation
306 of multiple arboviruses was a strength of our study. We were able to describe acute and
307 convalescent-phase arbovirus infection, frequent co-infection, and significant acute arbovirus
308 infection in asymptomatic pregnant women. Most importantly, with evaluation of ~6000
309 deliveries at our study clinics we describe a significant association of birth abnormalities in
310 pregnant women with acute arbovirus infection. Larger studies are needed to verify these
311 associations and identify risk factors for infant abnormalities given arboviral
312 infection/coinfection during pregnancy.

313 ZIKV, DENV and CHIKV are arboviruses of global public health importance. While
314 their dynamic epidemiology and association with clinical disease are actively studied in the
315 Americas and Asia, the biological consequences of these endemic viruses in Africa remain
316 poorly understood. Our study demonstrated low-level but persistent risk and exposure of all three
317 viruses in pregnant women in Nigeria. The significant rates of asymptomatic infection and
318 potential association with abnormal birth outcomes warrant further epidemiologic research to
319 reveal the burden of disease, risks of transmission, and immunopathogenesis linked to disease
320 outcomes of these viruses on the continent.

321 **Declaration of interests**

322 We declare no competing interests.

323 Acknowledgments

324 We acknowledge the invaluable support of our clinic and laboratory staff at JUTH and OLA that
325 enabled this study.

326 Role of the funding source

327 Research reported in this publication was supported by the National Institutes of Health under
328 award number R21AI137840 (Kanki) and R01AI149502 (Wang). The content is solely the
329 responsibility of the authors and does not necessarily represent the official views of the National
330 Institutes of Health.

331 References

- 332 1. Wilder-Smith A, Gubler DJ, Weaver SC, Monath TP, Heymann DL, Scott TW. Epidemic
333 arboviral diseases: priorities for research and public health. *Lancet Infect Dis.* 2017;17(3):e101-
334 e6. doi: 10.1016/S1473-3099(16)30518-7. PubMed PMID: 28011234.
- 335 2. Musso D, Rodriguez-Morales AJ, Levi JE, Cao-Lormeau VM, Gubler DJ. Unexpected
336 outbreaks of arbovirus infections: lessons learned from the Pacific and tropical America. *Lancet*
337 *Infect Dis.* 2018;18(11):e355-e61. doi: 10.1016/S1473-3099(18)30269-X. PubMed PMID:
338 29934112.
- 339 3. Aliota MT, Bassit L, Bradrick SS, Cox B, Garcia-Blanco MA, Gavegnano C, et al. Zika in
340 the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus
341 Network. *Antiviral Res.* 2017;144:223-46. doi: 10.1016/j.antiviral.2017.06.001. PubMed PMID:
342 28595824; PubMed Central PMCID: PMC5920658.
- 343 4. Lanciotti RS, Lambert AJ. Phylogenetic Analysis of Chikungunya Virus Strains
344 Circulating in the Western Hemisphere. *Am J Trop Med Hyg.* 2016;94(4):800-3. doi:
345 10.4269/ajtmh.15-0375. PubMed PMID: 26856917; PubMed Central PMCID: PMC4824221.
- 346 5. Charlier C, Beaudoin MC, Couderc T, Lortholary O, Lecuit M. Arboviruses and
347 pregnancy: maternal, fetal, and neonatal effects. *Lancet Child Adolesc Health.* 2017;1(2):134-46.
348 doi: 10.1016/S2352-4642(17)30021-4. PubMed PMID: 30169203.
- 349 6. WorldBank. Nigeria Data 2016 [20 June 2016]. Available from:
350 <http://data.worldbank.org/country/nigeria>.
- 351 7. Messina JP, Kraemer MU, Brady OJ, Pigott DM, Shearer FM, Weiss DJ, et al. Mapping
352 global environmental suitability for Zika virus. *Elife.* 2016;5. Epub 2016/04/20. doi:
353 10.7554/eLife.15272. PubMed PMID: 27090089; PubMed Central PMCID: 4889326.
- 354 8. Herrera BB, Chang CA, Hamel DJ, Mboup S, Ndiaye D, Imade G, et al. Continued
355 Transmission of Zika Virus in Humans in West Africa, 1992-2016. *J Infect Dis.*
356 2017;215(10):1546-50. Epub 2017/04/12. doi: 10.1093/infdis/jix182. PubMed PMID: 28398562;
357 PubMed Central PMCID: PMC5853591.

- 358 9. WHO. Zika situation report. Zika virus microcephaly Guillain-Barré syndrome [cited
359 2017 June 3, 2017]. Available from: [http://www.who.int/emergencies/zika-virus/situation-](http://www.who.int/emergencies/zika-virus/situation-report/10-march-2017/en/)
360 [report/10-march-2017/en/](http://www.who.int/emergencies/zika-virus/situation-report/10-march-2017/en/).
- 361 10. Weaver SC, Costa F, Garcia-Blanco MA, Ko AI, Ribeiro GS, Saade G, et al. Zika virus:
362 History, emergence, biology, and prospects for control. *Antiviral Res.* 2016;130:69-80. doi:
363 10.1016/j.antiviral.2016.03.010. PubMed PMID: 26996139; PubMed Central PMCID:
364 PMC4851879.
- 365 11. Amarasinghe A, Kuritsk JN, Letson GW, Margolis HS. Dengue virus infection in Africa.
366 *Emerg Infect Dis.* 2011;17(8):1349-54. doi: 10.3201/eid1708.101515. PubMed PMID: 21801609;
367 PubMed Central PMCID: PMC3381573.
- 368 12. Bravo JR, Guzman MG, Kouri GP. Why dengue haemorrhagic fever in Cuba? 1. Individual
369 risk factors for dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS). *Transactions of*
370 *the Royal Society of Tropical Medicine and Hygiene.* 1987;81(5):816-20. doi: 10.1016/0035-
371 9203(87)90041-1. PubMed PMID: 3450004.
- 372 13. Garcia G, Sierra B, Perez AB, Aguirre E, Rosado I, Gonzalez N, et al. Asymptomatic
373 dengue infection in a Cuban population confirms the protective role of the RR variant of the
374 FcγRIIIa polymorphism. *Am J Trop Med Hyg.* 2010;82(6):1153-6. doi:
375 10.4269/ajtmh.2010.09-0353. PubMed PMID: 20519616; PubMed Central PMCID:
376 PMC2877427.
- 377 14. Gubler DJ. The changing epidemiology of yellow fever and dengue, 1900 to 2003: full
378 circle? *Comparative immunology, microbiology and infectious diseases.* 2004;27(5):319-30. doi:
379 10.1016/j.cimid.2004.03.013. PubMed PMID: 15225982.
- 380 15. Paixao ES, Teixeira MG, Costa M, Rodrigues LC. Dengue during pregnancy and adverse
381 fetal outcomes: a systematic review and meta-analysis. *Lancet Infect Dis.* 2016;16(7):857-65. doi:
382 10.1016/S1473-3099(16)00088-8. PubMed PMID: 26949028.
- 383 16. Vazeille M, Mousson L, Martin E, Failloux AB. Orally co-Infected *Aedes albopictus* from
384 La Reunion Island, Indian Ocean, can deliver both dengue and chikungunya infectious viral
385 particles in their saliva. *PLoS Negl Trop Dis.* 2010;4(6):e706. Epub 2010/06/15. doi:
386 10.1371/journal.pntd.0000706. PubMed PMID: 20544013; PubMed Central PMCID:
387 PMC2882319.
- 388 17. Ruckert C, Weger-Lucarelli J, Garcia-Luna SM, Young MC, Byas AD, Murrieta RA, et al.
389 Impact of simultaneous exposure to arboviruses on infection and transmission by *Aedes aegypti*
390 mosquitoes. *Nat Commun.* 2017;8:15412. Epub 2017/05/20. doi: 10.1038/ncomms15412.
391 PubMed PMID: 28524874; PubMed Central PMCID: PMC5454532.
- 392 18. Goertz GP, Vogels CBF, Geertsema C, Koenraadt CJM, Pijlman GP. Mosquito co-
393 infection with Zika and chikungunya virus allows simultaneous transmission without affecting
394 vector competence of *Aedes aegypti*. *PLoS Negl Trop Dis.* 2017;11(6):e0005654. Epub
395 2017/06/02. doi: 10.1371/journal.pntd.0005654. PubMed PMID: 28570693; PubMed Central
396 PMCID: PMC5469501.
- 397 19. Vogels CBF, Ruckert C, Cavany SM, Perkins TA, Ebel GD, Grubaugh ND. Arbovirus
398 coinfection and co-transmission: A neglected public health concern? *PLoS Biol.*
399 2019;17(1):e3000130. Epub 20190122. doi: 10.1371/journal.pbio.3000130. PubMed PMID:
400 30668574; PubMed Central PMCID: PMC6358106.
- 401 20. Waggoner JJ, Gresh L, Vargas MJ, Ballesteros G, Tellez Y, Soda KJ, et al. Viremia and
402 Clinical Presentation in Nicaraguan Patients Infected With Zika Virus, Chikungunya Virus, and

- 403 Dengue Virus. *Clin Infect Dis*. 2016;63(12):1584-90. Epub 20160830. doi: 10.1093/cid/ciw589.
404 PubMed PMID: 27578819; PubMed Central PMCID: PMC5146717.
- 405 21. Borgherini G, Poubeau P, Staikowsky F, Lory M, Le Moullec N, Becquart JP, et al.
406 Outbreak of chikungunya on Reunion Island: early clinical and laboratory features in 157 adult
407 patients. *Clin Infect Dis*. 2007;44(11):1401-7. Epub 20070418. doi: 10.1086/517537. PubMed
408 PMID: 17479933.
- 409 22. Ramful D, Carbonnier M, Pasquet M, Bouhmani B, Ghazouani J, Noormahomed T, et al.
410 Mother-to-child transmission of Chikungunya virus infection. *Pediatr Infect Dis J*.
411 2007;26(9):811-5. Epub 2007/08/28. doi: 10.1097/INF.0b013e3180616d4f. PubMed PMID:
412 17721376.
- 413 23. Touret Y, Randrianaivo H, Michault A, Schuffenecker I, Kauffmann E, Lenglet Y, et al.
414 [Early maternal-fetal transmission of the Chikungunya virus]. *Presse Med*. 2006;35(11 Pt 1):1656-
415 8. Epub 2006/11/07. doi: 10.1016/S0755-4982(06)74874-6. PubMed PMID: 17086120.
- 416 24. Gerardin P, Barau G, Michault A, Bintner M, Randrianaivo H, Choker G, et al.
417 Multidisciplinary prospective study of mother-to-child chikungunya virus infections on the island
418 of La Reunion. *PLoS Med*. 2008;5(3):e60. doi: 10.1371/journal.pmed.0050060. PubMed PMID:
419 18351797; PubMed Central PMCID: PMC2267812.
- 420 25. Gerardin P, Samperiz S, Ramful D, Boumahni B, Bintner M, Alessandri JL, et al.
421 Neurocognitive outcome of children exposed to perinatal mother-to-child Chikungunya virus
422 infection: the CHIMERE cohort study on Reunion Island. *PLoS Negl Trop Dis*. 2014;8(7):e2996.
423 Epub 2014/07/18. doi: 10.1371/journal.pntd.0002996. PubMed PMID: 25033077; PubMed
424 Central PMCID: PMC4102444.
- 425 26. WHO. WHO Child Growth Standards: World Health Organization; 2007 [cited 2017].
426 Available from: http://www.who.int/childgrowth/standards/second_set/technical_report_2.pdf.
- 427 27. Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth
428 chart for preterm infants. *BMC pediatrics*. 2013;13:59. Epub 20130420. doi: 10.1186/1471-2431-
429 13-59. PubMed PMID: 23601190; PubMed Central PMCID: PMC3637477.
- 430 28. Chou JH, Roumiantsev S, Singh R. PediTools Electronic Growth Chart Calculators:
431 Applications in Clinical Care, Research, and Quality Improvement. *J Med Internet Res*.
432 2020;22(1):e16204. Epub 20200130. doi: 10.2196/16204. PubMed PMID: 32012066; PubMed
433 Central PMCID: PMC7058170.
- 434 29. Tsai WY, Youn HH, Brites C, Tsai JJ, Tyson J, Pedroso C, et al. Distinguishing Secondary
435 Dengue Virus Infection From Zika Virus Infection With Previous Dengue by a Combination of 3
436 Simple Serological Tests. *Clin Infect Dis*. 2017;65(11):1829-36. doi: 10.1093/cid/cix672. PubMed
437 PMID: 29020159; PubMed Central PMCID: PMC5850648.
- 438 30. Tsai WY, Driese K, Tsai JJ, Hsieh SC, Sznajder Granat R, Jenkins O, et al. Enzyme-linked
439 immunosorbent assays using virus-like particles containing mutations of conserved residues on
440 envelope protein can distinguish three flavivirus infections. *Emerg Microbes Infect*.
441 2020;9(1):1722-32. Epub 2020/07/21. doi: 10.1080/22221751.2020.1797540. PubMed PMID:
442 32684139; PubMed Central PMCID: PMC7473235.
- 443 31. Tsai WY, Chen HL, Tsai JJ, Dejnirattisai W, Jumnainsong A, Mongkolsapaya J, et al.
444 Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus
445 Particles: Implication for Novel Strategy for Dengue Vaccine. *J Virol*. 2018;92(23). doi:
446 10.1128/JVI.00556-18. PubMed PMID: 30185598; PubMed Central PMCID: PMC6232466.
- 447 32. Control CfD. Guidance for US Laboratories Testing for Zika Virus Infection 2017.
448 Available from: <https://www.cdc.gov/zika/laboratories/lab-guidance.html>.

- 449 33. Sagay SA, Hsieh S-C, Dai Y-C, Chang CA, Ogwuche J, Ige K, et al. Association of recent
450 Chikungunya virus infection of pregnant women with intrauterine transmission and abnormal
451 infant outcomes in Nigeria. submitted. 2023.
- 452 34. Tsai JJ, Liu CK, Tsai WY, Liu LT, Tyson J, Tsai CY, et al. Seroprevalence of dengue virus
453 in two districts of Kaohsiung City after the largest dengue outbreak in Taiwan since World War II.
454 PLoS Negl Trop Dis. 2018;12(10):e0006879. Epub 2018/10/26. doi:
455 10.1371/journal.pntd.0006879. PubMed PMID: 30356316; PubMed Central PMCID:
456 PMC6218099
- 457 35. Tyson J, Tsai WY, Tsai JJ, Brites C, Massgard L, Ha Youn H, et al. Combination of
458 Nonstructural Protein 1-Based Enzyme-Linked Immunosorbent Assays Can Detect and
459 Distinguish Various Dengue Virus and Zika Virus Infections. J Clin Microbiol. 2019;57(2). doi:
460 10.1128/JCM.01464-18. PubMed PMID: 30429254; PubMed Central PMCID: PMC6355536.
- 461 36. Houg HS, Chung-Ming Chen R, Vaughn DW, Kanesa-athan N. Development of a
462 fluorogenic RT-PCR system for quantitative identification of dengue virus serotypes 1-4 using
463 conserved and serotype-specific 3' noncoding sequences. J Virol Methods. 2001;95(1-2):19-32.
464 doi: 10.1016/s0166-0934(01)00280-4. PubMed PMID: 11377710.
- 465 37. Waggoner JJ, Gresh L, Mohamed-Hadley A, Ballesteros G, Davila MJ, Tellez Y, et al.
466 Single-Reaction Multiplex Reverse Transcription PCR for Detection of Zika, Chikungunya, and
467 Dengue Viruses. Emerg Infect Dis. 2016;22(7):1295-7. Epub 20160715. doi:
468 10.3201/eid2207.160326. PubMed PMID: 27184629; PubMed Central PMCID: PMC4918162.
- 469 38. Brasil P, Calvet GA, Siqueira AM, Wakimoto M, de Sequeira PC, Nobre A, et al. Zika
470 Virus Outbreak in Rio de Janeiro, Brazil: Clinical Characterization, Epidemiological and
471 Virological Aspects. PLoS Negl Trop Dis. 2016;10(4):e0004636. Epub 2016/04/14. doi:
472 10.1371/journal.pntd.0004636. PubMed PMID: 27070912; PubMed Central PMCID:
473 PMC4829157.
- 474 39. Villamil-Gomez WE, Rodriguez-Morales AJ, Uribe-Garcia AM, Gonzalez-Arismendy E,
475 Castellanos JE, Calvo EP, et al. Zika, dengue, and chikungunya co-infection in a pregnant woman
476 from Colombia. Int J Infect Dis. 2016;51:135-8. Epub 2016/10/26. doi: 10.1016/j.ijid.2016.07.017.
477 PubMed PMID: 27497951.
- 478 40. Barr KL, Vaidhyanathan V. Chikungunya in Infants and Children: Is Pathogenesis
479 Increasing? Viruses. 2019;11(3). Epub 2019/03/27. doi: 10.3390/v11030294. PubMed PMID:
480 30909568; PubMed Central PMCID: PMC6466311.
- 481 41. Mathe P, Egah DZ, Muller JA, Shehu NY, Obishakin ET, Shwe DD, et al. Low Zika virus
482 seroprevalence among pregnant women in North Central Nigeria, 2016. J Clin Virol. 2018;105:35-
483 40. Epub 20180526. doi: 10.1016/j.jcv.2018.05.011. PubMed PMID: 29885620.
- 484 42. Aubry F, Dabo S, Manet C, Filipovic I, Rose NH, Miot EF, et al. Enhanced Zika virus
485 susceptibility of globally invasive Aedes aegypti populations. Science. 2020;370(6519):991-6.
486 doi: 10.1126/science.abd3663. PubMed PMID: 33214283.
- 487 43. Sasmono RT, Santoso MS. Movement dynamics: reduced dengue cases during the
488 COVID-19 pandemic. Lancet Infect Dis. 2022;22(5):570-1. Epub 20220302. doi: 10.1016/S1473-
489 3099(22)00062-7. PubMed PMID: 35247322; PubMed Central PMCID: PMC8890753.
- 490 44. Chen Y, Li N, Lourenco J, Wang L, Cazelles B, Dong L, et al. Measuring the effects of
491 COVID-19-related disruption on dengue transmission in southeast Asia and Latin America: a
492 statistical modelling study. Lancet Infect Dis. 2022;22(5):657-67. Epub 20220302. doi:
493 10.1016/S1473-3099(22)00025-1. PubMed PMID: 35247320; PubMed Central PMCID:
494 PMC8890758.

- 495 45. Montoya M, Gresh L, Mercado JC, Williams KL, Vargas MJ, Gutierrez G, et al.
496 Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the
497 time interval between infections and study year. *PLoS Negl Trop Dis*. 2013;7(8):e2357. doi:
498 10.1371/journal.pntd.0002357. PubMed PMID: 23951377; PubMed Central PMCID:
499 PMC3738476.
- 500 46. Endy TP, Anderson KB, Nisalak A, Yoon IK, Green S, Rothman AL, et al. Determinants
501 of inapparent and symptomatic dengue infection in a prospective study of primary school children
502 in Kamphaeng Phet, Thailand. *PLoS Negl Trop Dis*. 2011;5(3):e975. Epub 20110301. doi:
503 10.1371/journal.pntd.0000975. PubMed PMID: 21390158; PubMed Central PMCID:
504 PMC3046956.
- 505 47. Bustos Carrillo F, Collado D, Sanchez N, Ojeda S, Lopez Mercado B, Burger-Calderon R,
506 et al. Epidemiological Evidence for Lineage-Specific Differences in the Risk of Inapparent
507 Chikungunya Virus Infection. *J Virol*. 2019;93(4). Epub 20190205. doi: 10.1128/JVI.01622-18.
508 PubMed PMID: 30463967; PubMed Central PMCID: PMC6364014.
- 509 48. Bettis AA, L'Azou Jackson M, Yoon IK, Breugelmans JG, Goios A, Gubler DJ, et al. The
510 global epidemiology of chikungunya from 1999 to 2020: A systematic literature review to inform
511 the development and introduction of vaccines. *PLoS Negl Trop Dis*. 2022;16(1):e0010069. Epub
512 20220112. doi: 10.1371/journal.pntd.0010069. PubMed PMID: 35020717; PubMed Central
513 PMCID: PMC8789145.
- 514 49. Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, et al. Zika virus
515 outbreak on Yap Island, Federated States of Micronesia. *N Engl J Med*. 2009;360(24):2536-43.
516 doi: 10.1056/NEJMoa0805715. PubMed PMID: 19516034.
- 517 50. Eppes C, Rac M, Dunn J, Versalovic J, Murray KO, Suter MA, et al. Testing for Zika virus
518 infection in pregnancy: key concepts to deal with an emerging epidemic. *American journal of*
519 *obstetrics and gynecology*. 2017;216(3):209-25. doi: 10.1016/j.ajog.2017.01.020. PubMed PMID:
520 28126366.
- 521 51. Abdullahi IN, Akande AO, Muhammed Y, Rogo LD, Oderinde BS. Prevalence Pattern of
522 Chikungunya Virus Infection in Nigeria: A Four Decade Systematic Review and Meta-analysis.
523 *Pathog Glob Health*. 2020;114(3):111-6. Epub 20200319. doi: 10.1080/20477724.2020.1743087.
524 PubMed PMID: 32191166; PubMed Central PMCID: PMC7241486.
- 525 52. van der Eijk AA, van Genderen PJ, Verdijk RM, Reusken CB, Mogling R, van Kampen JJ,
526 et al. Miscarriage Associated with Zika Virus Infection. *N Engl J Med*. 2016;375(10):1002-4. Epub
527 20160727. doi: 10.1056/NEJMc1605898. PubMed PMID: 27463941.
- 528 53. Arragain L, Dupont-Rouzeyrol M, O'Connor O, Sigur N, Grangeon JP, Huguon E, et al.
529 Vertical Transmission of Dengue Virus in the Peripartum Period and Viral Kinetics in Newborns
530 and Breast Milk: New Data. *J Pediatric Infect Dis Soc*. 2017;6(4):324-31. doi:
531 10.1093/jpids/piw058. PubMed PMID: 27760799.

532

533


534

535

536

537 Figure 1: Venn diagram of acute (IgM) ZIKV, DENV and CHIKV infection


538 Women with any IgM reactivity (200, 19.9%) by arbovirus.



539
540
541
542
543
544
545
546
547
548
549
550

551 Figure 2: Acute (IgM) arbovirus infection (2019-2022)

552 Seroprevalence (left axis) and number of women tested (right axis); rainy season indicated by
553 rain cloud.



554

555

556

557

558

559

560

561

562 Table 1. Prevalence of Zika, chikungunya, and dengue infection (ChemBio IgM+) among pregnant women at Jos University
563 Teaching Hospital and Our Lady of Apostles Hospital, Jos, Nigeria, April 2019–January 2022*

	Any IgM+ (with or without IgG+)			IgG+-only		
	Symptomatic, no. (%)	Asymptomatic, no. (%)	Total, no. (%)	Symptomatic, no. (%)	Asymptomatic, no. (%)	Total, no. (%)
Total	787	219	1006	787	219	1006
ZIKV	10 (1.3%)	4 (1.8%)	14 (1.4%)	4 (0.5%)	0 (0.0%)	4 (0.4%)
CHIKV	53 (6.7%)	24 (11.0%)	77 (7.7%)	38 (4.8%)	12 (5.5%)	50 (5.0%)
DENV	39 (5.0%)	21 (9.6%)	60 (6.0%)	26 (3.3%)	5 (2.3%)	31 (3.1%)
ZIKV & CHIKV	6 (0.8%)	3 (1.4%)	9 (0.9%)	3 (0.4%)	0 (0.0%)	3 (0.3%)
ZIKV & DENV	5 (0.6%)	2 (0.9%)	7 (0.7%)	5 (0.6%)	3 (1.4%)	8 (0.8%)
CHIKV & DENV	12 (1.5%)	13 (5.9%)	25 (2.5%)	10 (1.3%)	4 (1.8%)	14 (1.4%)
ZIKV, CHIKV, & DENV	7 (0.9%)	1 (0.5%)	8 (0.8%)	2 (0.3%)	0 (0.0%)	2 (0.2%)
Arbovirus reactive	132 (16.8%)	68 (31.1%)	200 (19.9%)	88 (11.2%)	24 (11.0%)	112 (11.1%)

*IgM, immunoglobulin M; IgG, immunoglobulin G; ZIKV, Zika virus; CHIKV, chikungunya virus; DENV, dengue virus.

564

565

566
567

Table 2. Baseline characteristics and risk factors for Zika, dengue, and chikungunya infection (Chembio IgM+) among pregnant women in Jos, Nigeria, April 2019-January 2022*

	Bivariate analysis			Logistic regression analysis			
	ZIKV/DENV/CHIKV negative or IgG+ only, no. (%)†	ZIKV/DENV/CHIKV IgM+, no. (%)	Chi-square p value	Unadjusted OR (95% CI)‡	Chi-square p value	Adjusted OR (95% CI)	Chi-square p value
Demographic characteristics							
Clinic							
JUTH	420 (87.9)	58 (12.1)	<.001	Ref			
OLA	385 (72.9)	143 (27.1)		2.69 (1.92–3.76)	<.001		
Year							
Apr 2019–Mar 2020	241 (73.0)	89 (27.0)	.001	Ref		Ref	
Apr 2020–Mar 2021	309 (84.0)	59 (16.0)		.52 (.32–.83)	.007	.49 (.31–.78)	.002
Apr 2021–Jan 2022	255 (82.8)	53 (17.2)		.56 (.15–2.13)	.398	.50 (.16–1.62)	.249
Age, years							
18–24	243 (85.3)	42 (14.7)	.039	Ref		Ref	
25–34	415 (77.9)	118 (22.1)		1.65 (1.25–2.17)	<.001	1.29 (1.12–1.49)	<.001
35–45	138 (80.7)	33 (19.3)		1.38 (.86–2.22)	.178	1.16 (.86–1.55)	.329
Trimester (weeks)							
1 (≤12)	87 (79.8)	22 (20.2)	.520	Ref			
2 (13–27)	425 (81.3)	98 (18.7)		.91 (.64–1.30)	.608		
3 (≥28)	286 (78.1)	80 (21.9)		1.11 (.71–1.74)	.660		
Ethnic group							
Hausa/Fulani	299 (85.7)	50 (14.3)	.018	Ref			
Yoruba	36 (81.8)	8 (18.2)		1.33 (.49–3.57)	.573		
Igbo	102 (75.6)	33 (24.4)		1.93 (1.14–3.27)	.014		
Other	356 (77.9)	101 (22.1)		1.70 (1.57–1.84)	<.001		
Occupation							
Student	121 (80.1)	30 (19.9)	.144	Ref		Ref	
Housewife	268 (84.0)	51 (16.0)		.77 (.45–1.31)	.332	.85 (.69–1.05)	.133
Employed	387 (78.0)	109 (22.0)		1.14 (.84–1.54)	.408	.94 (.80–1.11)	.461
Unemployed	13 (72.2)	5 (27.8)		1.55 (.28–8.65)	.616	2.21 (1.05–4.67)	.038
Marital status							
Single	8 (88.9)	1 (11.1)	.525	Ref	.528		
Married	770 (80.5)	187 (19.5)		1.94 (.25–15.30)			
Education							
None/primary	32 (78.1)	9 (22.0)	.916	Ref			
Secondary	334 (80.5)	81 (19.5)		.86 (.59–1.26)	.445		
Tertiary	410 (79.8)	104 (20.2)		.90 (.41–1.97)	.795		
Mosquito exposure							
Season							
Dry (Nov 1–Mar 31)	274 (82.3)	59 (17.7)	.207	Ref			
Rainy (Apr 1–Oct 31)	531 (78.9)	142 (21.1)		1.24 (1.24–1.25)	<.001		
Neighborhood							
City	352 (80.7)	84 (19.3)	.557	Ref			
Suburb	414 (80.4)	101 (19.6)		1.02 (.62–1.68)	.931		
Rural	31 (73.8)	11 (26.2)		1.49 (.71–3.12)	.293		
Work setting							
City	352 (80.2)	87 (19.8)	.321	Ref			
Suburb	415 (81.1)	97 (19.0)		.95 (.60–1.49)	.81		
Rural	30 (71.4)	12 (28.6)		1.62 (.80–3.27)	.18		
Majority day environment							
Indoor	466 (85.4)	80 (14.7)	<.001	Ref		Ref	
Outdoor	326 (74.1)	114 (25.9)		2.04 (1.65–2.51)	<.001	1.78 (1.61–1.97)	<.001
Travel to area with mosquitos							
No	646 (81.5)	147 (18.5)	.053	Ref		Ref	
Yes	122 (74.9)	41 (25.2)		1.48 (.66–3.33)	.347	1.43 (1.01–2.03)	.043
Recent mosquito bite(s) (<2 weeks)							
No	316 (85.4)	54 (14.6)	.001	Ref			
Yes	471 (76.2)	147 (23.8)		1.83 (.99–3.38)	.055		
Prior mosquito bite(s) (>2 weeks)							
No	227 (85.3)	39 (14.7)	.007	Ref		Ref	

568
569
570
571
572

Yes 557 (77.6) 161 (22.4) 1.68 (1.02-2.78) .042 2.16 (2.15-2.17) <.001

* IgM, immunoglobulin M; ZIKV, Zika virus; DENV, dengue virus; CHIKV, chikungunya virus; IgG, immunoglobulin G; OR, odds ratio; CI, confidence interval; JUTH, Jos University Teaching Hospital; Ref, reference category; OLA, Our Lady of Apostles Hospital.

†Row percentages shown.

‡Site used as cluster variable in logistic regression analyses.

573

574
575
576

Table 3. Abnormal delivery outcomes among study infants born to mothers with any acute Zika, dengue, or chikungunya infection versus infants in birth registers at Jos University Teaching Hospital and Our Lady of Apostles Hospital, Jos, Nigeria, May 2019–May 2021*†

	Birth registers, no. (%)‡	Study infants born to any Chembio ZIKV/DENV/CHIKV IgM+ mother, no. (%)	Fisher's exact p value	Study infants born to any ZIKV/DENV/CHIKV IgM-confirmed mother, no. (%)	Fisher's exact p value
Total	5930	101		37	
Macerated stillbirth	117 (2.0%)	6 (5.9%)	.017	3 (8.1%)	.038
Fresh stillbirth	81 (1.4%)	0 (0.0%)	.647	0 (0.0%)	1
Preterm	294 (5.0%)	6 (5.9%)	.640	4 (10.8%)	.111
Asymmetric intrauterine growth retardation	0 (0.0%)	1 (1.0%)	.017	0 (0.0%)	...
Neural tube defects	7 (0.1%)	0 (0.0%)	1	0 (0.0%)	1
<i>Anencephalocele</i> §	3 (0.1%)	0 (0.0%)	1	0 (0.0%)	1
<i>Spina bifida</i>	2 (0.0%)	0 (0.0%)	1	0 (0.0%)	1
<i>Encephalocele</i>	1 (0.0%)	0 (0.0%)	1	0 (0.0%)	1
<i>Holoprosencephaly</i>	1 (0.0%)	0 (0.0%)	1	0 (0.0%)	1
Other CNS abnormalities	34 (0.6%)	6 (5.9%)	<.001	2 (5.4%)	.021
<i>Microcephaly</i>	32 (0.5%)	6 (5.9%)	<.001	2 (5.4%)	.019
<i>Hydrocephalus</i>	2 (0.0%)	0 (0.0%)	1	0 (0.0%)	1
Cleft lip/palate	0 (0.0%)	1 (1.0%)	.017	1 (2.7%)	.006
Gastrointestinal defects	4 (0.1%)	0 (0.0%)	1	0 (0.0%)	1
<i>Omphalocele</i>	2 (0.0%)	0 (0.0%)	1	0 (0.0%)	1
<i>Duodenal atresia</i>	2 (0.0%)	0 (0.0%)	1	0 (0.0%)	1
Limb defects	1 (0.0%)	1 (1.0%)	.033	1 (2.7%)	.012
<i>Clubbed foot</i>	1 (0.0%)	0 (0.0%)	1	0 (0.0%)	1
<i>Polydactyly</i>	0 (0.0%)	1 (1.0%)	.017	1 (2.7%)	.006
Multiple gross congenital anomalies¶	3 (0.1%)	3 (3.0%)	<.001	2 (5.4%)	<.001
Any abnormality#	541 (9.1%)	17 (16.8%)	.014	9 (24.3%)	.005

577
578
579
580
581
582
583
584
585
586
587
588

*ZIKV, Zika virus; DENV, dengue virus; CHIKV, chikungunya virus; IgM, immunoglobulin M.

†Data shown includes adverse and gross abnormal outcomes recorded in hospital birth registers; other outcomes, such as neonatal sepsis and jaundice, are not shown. 101 study infants born to mothers with a Chembio IgM+ rapid test result during the time period were observed at birth. Among them, 37 of the mothers had their IgM+ status confirmed by ELISA or neutralization assay.

‡Column percentages shown.

§Italicized outcomes are subsets of their larger category. Numbers, percentages, and p values are shown for each outcome and category, if applicable.

¶Among the three study infants with multiple congenital anomalies, one also had cleft lip/palate, asymmetric microcephaly, craniocynostosis, hypotonia, and died on day 2; another also had loss of consciousness, seizures, hypotonia, and sustained microcephaly through 6 months; another was a stillbirth with facial dysmorphism.

#Study infants that fell under multiple abnormal categories were only counted once under "Any abnormality."